The FLAMIN-GO project implemented a two-level dissemination strategy to ensure broad visibility of its results and to maximize both international and European impact.
At the global level, the project findings were presented in Australia (Sydney) at the Musculoskeletal Research Centre of the University of Sydney (3/12/2025), within the activities of the Sydney MSK Flagship Research Centre. This internationally recognized centre plays a leading role in musculoskeletal research, clinical innovation, and professional training, operating within a strong musculoskeletal research ecosystem. Australia also hosts a well-established national rheumatology biobank, the Australian Arthritis and Autoimmune Biobank Collaborative (A3BC), which has a significant focus on translational and precision medicine approaches.
During this event were presented the overall FLAMIN-GO outcomes, with particular emphasis on the clinical trial results and their translational implications. The same dissemination event was subsequently replicated in Adelaide, further broadening outreach within the Australian musculoskeletal and rheumatology research community.
At the European level, dissemination took place in Novara (Italy) (22/11/25) at the Università del Piemonte Orientale (UPO) during the final project conference. On this occasion, the main outcomes, methodological advancements, and clinical implications of the FLAMIN-GO project were presented to academics, healthcare professionals, and key stakeholders. The event strengthened knowledge exchange between research and clinical practice and reinforced the project’s international dimension.
